CERTIFICATE OF MAILING

hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231, on the date appearing below.

ELI LILLY AND COMPANY

PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants

Krushinski, et. al

Serial No.

09/890,741

Filed

December 4, 2001

For

5-HT1F AGONISTS

Docket No. :

X-11704

Group Art Unit:

1614

INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents Washington, D.C. 20231 Sir:

As a means of complying with the duty of disclosure, Applicants submit an "Information Disclosure Citation in an Application" on a modified Form PTO-1449 and provide a copy of each of the listed documents for consideration by the Examiner.

Since this Statement is being filed in accordance with 37 C.F.R. 1.97(b), Applicants submit that no additional fee is required.

Applicants request consideration of this information.

Respectfully submitted,

R. Craig Tucker

Attorney for Applicants Registration No. 45,165

Phone: 317-433-9829

Eli Lilly and Company Patent Division/RCT Lilly Corporate Center Indianapolis, IN 46285